Successful results for phase III study with oral Laquinimod

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Successful results for phase III study with oral Laquinimod

Postby MSUK » Thu Dec 09, 2010 1:29 am

Image


Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo.

Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved..... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1735
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2088
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users